Multiple Criteria Decision Analysis for Health Technology Assessment

Published on Nov 1, 2012in Value in Health5.037
· DOI :10.1016/j.jval.2012.06.015
Praveen Thokala19
Estimated H-index: 19
(University of Sheffield),
Alejandra Duenas11
Estimated H-index: 11
(Lille Catholic University)
Abstract Objectives Multicriteria decision analysis (MCDA) has been suggested by some researchers as a method to capture the benefits beyond quality adjusted life-years in a transparent and consistent manner. The objectives of this article were to analyze the possible application of MCDA approaches in health technology assessment and to describe their relative advantages and disadvantages. Methods This article begins with an introduction to the most common types of MCDA models and a critical review of state-of-the-art methods for incorporating multiple criteria in health technology assessment. An overview of MCDA is provided and is compared against the current UK National Institute for Health and Clinical Excellence health technology appraisal process. A generic MCDA modeling approach is described, and the different MCDA modeling approaches are applied to a hypothetical case study. Results A comparison of the different MCDA approaches is provided, and the generic issues that need consideration before the application of MCDA in health technology assessment are examined. Conclusions There are general practical issues that might arise from using an MCDA approach, and it is suggested that appropriate care be taken to ensure the success of MCDA techniques in the appraisal process.
  • References (60)
  • Citations (164)
📖 Papers frequently viewed together
377 Citations
2,009 Citations
90 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Sung Eun ParkH-Index: 2
#2Sang Hee LimH-Index: 2
Last. So Young YiH-Index: 2
view all 8 authors...
Abstract Objective The South Korean positive list system in pharmaceutical reimbursement was introduced by the Health Care System Reform Act implemented in December 2006. This study introduces this positive list system (PLS), and reports on an evaluation of two years of operation. In addition, decision-making factors are evaluated and current issues and solutions discussed. Methods We analyzed 91 submissions with reimbursement decisions completed by December 31, 2008. Submission characteristics ...
23 CitationsSource
#1G. DoriniH-Index: 4
#2Zoran Kapelan (University of Exeter)H-Index: 38
Last. Adisa Azapagic (University of Manchester)H-Index: 48
view all 3 authors...
In real life, decisions are usually made by comparing different options with respect to several, often conflicting criteria. This requires subjective judgements on the importance of different criteria by DMs and increases uncertainty in decision making. This article demonstrates how uncertainty can be handled in multi-criteria decision situations using Compromise Programming, one of the Multi-criteria Decision Analysis (MCDA) techniques. Uncertainty is characterised using a probabilistic approac...
51 CitationsSource
#1N. DevlinH-Index: 1
#2J. SussexH-Index: 1
What a health care system should pay for depends, of course, on the health gain that results. Health technology assessment (HTA) and cost-effectiveness analysis have become the core for many such decisions, by NICE in the UK and by similar bodies elsewhere. Other factors, however, also are taken into account by the governments and insurers who fund health care. These typically include - the impact of decisions on social equity[]; the quality of the patient experience; ramifications for the wider...
79 Citations
Current models of healthcare quality recommend that patient management decisions be evidence based and patient centered. Evidence-based decisions require a thorough understanding of current information regarding the natural history of disease and the anticipated outcomes of different management options. Patient-centered decisions incorporate patient preferences, values, and unique personal circumstances in the decision-making process, and actively involve both patients and healthcare providers a...
124 CitationsSource
#1Dana P. Goldman (AN: RAND Corporation)H-Index: 48
#2Darius N. Lakdawalla (AN: RAND Corporation)H-Index: 39
Last. Wesley Yin (BU: Boston University)H-Index: 11
view all 4 authors...
Pricing, reimbursements and coverage decisions for medical innovations and services are complex. In many countries, valuing medical technologies is the responsibility of national health-care systems that strive for distributive efficiency under fiscal constraints on medical spending. In the UK, the National Institute for Health and Clinical Excellence (NICE) is charged with the difficult task of assessing new and existing medical technologies, and making recommendations that guide NHS coverage d...
28 CitationsSource
#1David J. Nutt (Imperial College London)H-Index: 89
#2Leslie A. King (European Monitoring Centre for Drugs and Drug Addiction)H-Index: 17
Last. Lawrence D. Phillips (LSE: London School of Economics and Political Science)H-Index: 29
view all 3 authors...
Summary Background Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK. Methods Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the h...
746 CitationsSource
The Patient-Centered Outcomes Research Institute . . . shall not develop or employ a dollars per quality adjusted life year (or similar measure that discounts the value of a life because of an individual's disability) as a threshold to establish what type of health care is cost effective or recommended. The Secretary shall not utilize such an adjusted life year (or such a similar measure) as a threshold to determine coverage, reimbursement, or incentive programs under title XVIII. — The Patient ...
183 CitationsSource
#1Rudolf Klein (LSE: London School of Economics and Political Science)H-Index: 21
34 CitationsSource
The National Health Service (NHS) should reward innovation it values. This will enable the NHS and the United Kingdom (UK) economy to benefit and impact positively on the Research and Development (R&D) decision making of companies. The National Institute for Health and Clinical Excellence (NICE) currently seeks to do this on behalf of the NHS. Yet the Office of Fair Trading proposals for Value Based Pricing add price setting powers – initially for the Department of Health (DH) and then for NICE....
38 CitationsSource
#1Rob Baltussen (Radboud University Nijmegen)H-Index: 41
#2Sitaporn Youngkong (Radboud University Nijmegen)H-Index: 6
Last. Louis W. Niessen (Johns Hopkins University)H-Index: 33
view all 4 authors...
This paper capitalizes on a first set of experiences on the application of multi-criteria decision analysis (MCDA) in seven low- and middle-income settings. It thereby reacts to a recent paper by Peacock et al., highlighting the potential of MCDA to guide policy makers in highly specific decision-making contexts. We argue that MCDA also has a broader application in setting priorities in health, i.e. to indicate general perceptions on priorities without defining the allocation of resources in a p...
68 CitationsSource
Cited By164
#1Fatma Kutlu Gündoğdu (Turkish Air Force Academy)H-Index: 1
#2Cengiz Kahraman (ITU: Istanbul Technical University)H-Index: 59
Health-care service quality is the core of the medical institution’s management. However, the measurement of service quality is difficult by classical measurement approaches. The fuzzy set theory can capture this difficulty through its linguistic approaches. The extensions of ordinary fuzzy sets such as intuitionistic fuzzy sets (IFS), Pythagorean fuzzy sets (PFS), and neutrosophic sets (NS), whose membership functions are based on three dimensions, aim at collecting experts’ judgments more info...
#1Marco Cinelli (PUT: Poznań University of Technology)H-Index: 9
#2Miłosz Kadziński (PUT: Poznań University of Technology)H-Index: 19
Last. Roman Słowiński (PUT: Poznań University of Technology)H-Index: 71
view all 4 authors...
Abstract Decision making is a complex task that involves a multitude of perspectives, constraints, and variables. Multiple Criteria Decision Analysis (MCDA) is a process that has been used for several decades to support decision making. It includes a series of steps that systematically help Decision Maker(s) (DM(s)) and stakeholders in structuring a decision making problem, identifying their preferences, and building a decision recommendation consistent with those preferences. Over the last deca...
The instrumental-ceremonial dichotomy is the analytical concern emphasized in instrumental analysis by original institutional economists for making welfare decisions. Paul Dale Bush and Wolfram Els...
Abstract Background Many commercial and artisanal devices are utilized for temporary abdominal closure in patients being managed with an open abdomen for abdominal sepsis. The costs of materials required to treat patients with an open abdomen varies drastically. In Costa Rica, due to the lack of accurate information relating to the actual cost to manage a patient entails that the method with the least expensive materials is usually selected. Study design A single-center retrospective review of 4...
#1Brian P. Reddy (University of Sheffield)
#2Stephen J. Walters (University of Sheffield)H-Index: 52
Last. M. P. Kelly (University of Cambridge)H-Index: 48
view all 5 authors...
Background : The National Institute for Health and Care Excellence (NICE) use economic modelling to inform judgements whenever further insight is required for decision-making. Doing so for public health guidance poses several challenges. The study’s objective was to investigate the level of heterogeneity in NICE’s public health economic models with regards to economic evaluation techniques, perspectives on outcomes and the measurement of non-health benefits. Methods : A review of all economic mo...
#1John A. Graves (Vandy: Vanderbilt University)H-Index: 12
#2Shawn P. Garbett (Vandy: Vanderbilt University)H-Index: 9
Last. Josh F. Peterson (Vandy: Vanderbilt University)H-Index: 40
view all 5 authors...
We discuss tradeoffs and errors associated with approaches to modeling health economic decisions. Through an application in pharmacogenomic (PGx) testing to guide drug selection for individuals with a genetic variant, we assessed model accuracy, optimal decisions and computation time for an identical decision scenario modeled four ways: using (1) coupled-time differential equations [DEQ]; (2) a cohort-based discrete-time state transition model [MARKOV]; (3) an individual discrete-time state tran...
#1Carina Schey (UG: University of Groningen)H-Index: 3
#2Maarten J. Postma (UG: University of Groningen)H-Index: 47
Last. Mark P. Connolly (UG: University of Groningen)H-Index: 10
view all 5 authors...
Background: There is a perception held by payers that orphan products are expensive. As a result, the current health technology assessment systems might be too restrictive for orphan drugs, therefore potentially denying patients access to life-saving medicines. While price is important, it should be considered in relation to a broader range of disease-related product attributes that are not necessarily considered by many health technology assessment agencies. To overcome these challenges, multi-...
#1Laura Panattoni (Fred Hutchinson Cancer Research Center)H-Index: 3
#2Charles E. Phelps (UR: University of Rochester)H-Index: 35
Last. Scott D. Ramsey (Fred Hutchinson Cancer Research Center)H-Index: 61
view all 7 authors...
OBJECTIVES: Chemotherapy is increasingly a preference-based choice among women diagnosed with early-stage breast cancer. Multicriteria decision analysis (MCDA) is a promising but underutilized method to facilitate shared decision making. We explored the feasibility of conducting an MCDA using direct rank ordering versus a time trade-off (TTO) to assess chemotherapy choice in a large population-based sample. METHODS: We surveyed 904 early-stage breast cancer survivors who were within 5 years of d...
#1Necla Öztürk (Marmara University)H-Index: 1
#2Hakan TozanH-Index: 10
Last. Ozalp Vayvay (Marmara University)H-Index: 12
view all 3 authors...
Background: This paper presents a generic Multi-Criteria Decision Analysis (MCDA) model for Health Technology Assessment (HTA) decision-making, which can be applied to a wide range of HTA studies, regardless of the healthcare technology type under consideration. Methods: The HTA Core Model® of EUnetHTA was chosen as a basis for the development of the MCDA model because of its common acceptance among European Union countries. Validation of MCDA4HTA was carried out by an application with the HTA s...
#1Vusal Babashov (U of O: University of Ottawa)
#2Sarah Ben Amor (U of O: University of Ottawa)H-Index: 4
Last. Gilles Reinhardt (U of O: University of Ottawa)
view all 3 authors...
Background. Reviewing drugs to determine coverage or reimbursement level is a complex process that involves significant time and expertise. Review boards gather evidence from the submission provided, input from clinicians and patients, and results of clinical and economic reviews. This information consists of assessments on multiple criteria that often conflict with one another. Multiple-criteria decision analysis (MCDA) includes methods to address complex decision making problems with conflicti...